The Vitamin D Analog 1α,25-Dihydroxy-2β-(3-Hydroxypropyloxy) Vitamin D3 (Eldecalcitol) is a Potent Regulator of Calcium and Phosphate Metabolism
- 347 Downloads
The vitamin D analog 1α,25-dihydroxy-2β-(3-hydroxypropyloxy)vitamin D3 (ED-71 or eldecalcitol) has been developed for treatment of osteoporosis, but its effects on mineral metabolism have not been investigated in detail. In the present study, we compared the effects of eldecalcitol and calcitriol on calcium (Ca) and phosphate (Pi) handling in rats. Oral administration of eldecalcitol (0, 7.5, 20, or 50 pmol) q.o.d. for 2 weeks dose-dependently increased ionized Ca, intestinal Ca absorption, and urinary Ca excretion, while these doses of calcitriol had no significant effects. The highest dose of eldecalcitol did not alter serum Pi but stimulated both intestinal Pi absorption and urinary Pi excretion; the latter was attributable, in part, to increased serum FGF-23. The effects of high-dose eldecalcitol on Ca and Pi absorption and urinary excretion and FGF-23 persisted for several days following cessation of treatment. The higher potency of eldecalcitol on Ca and Pi handling was also observed in parathyroidectomized rats infused with PTH, excluding a role for differential regulation of PTH. Direct measurement of duodenal Ca absorption by the in situ loop method confirmed the higher potency of eldecalcitol in this segment via induction of TRPV6. These studies indicated that with chronic administration eldecalcitol is more potent than calcitriol at stimulating intestinal absorption of Ca and Pi, as well as FGF-23. The mechanisms responsible for the higher potency of eldecalcitol are speculated to be its higher vitamin D-binding protein (DBP) affinity and resistance to metabolism.
KeywordsIntestinal mineral absorption Mineral and electrolyte metabolism PTH/PTHrP Vitamin D
This work was supported by a research grant from Chugai Pharmaceutical. The authors thank Jane Boudreaux for assistance with the in vivo studies.
- 3.Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y, Nishii Y (1994) A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 54(2):142–149PubMedCrossRefGoogle Scholar
- 5.Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T (2005) A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 90(9):5031–5036PubMedCrossRefGoogle Scholar
- 7.Hatakeyama S, Nagashima S, Imai N, Takahashi K, Ishihara J, Sugita A, Nihei T, Saito H, Takahashi F, Kubodera N (2007) Synthesis and biological evaluation of a 3-position epimer of 1alpha, 25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71). J Steroid Biochem Mol Biol 103(3–5):222–226PubMedCrossRefGoogle Scholar
- 8.Flanagan JN, Zheng S, Chiang KC, Kittaka A, Sakaki T, Nakabayashi S, Zhao X, Spanjaard RA, Persons KS, Mathieu JS, Holick MF, Chen TC (2009) Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha, 25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 29(9):3547–3553PubMedGoogle Scholar
- 20.Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R, Carmeliet G (2001) Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci USA 98(23):13324–13329PubMedCrossRefGoogle Scholar